# [Comment] Remibrutinib: a high-efficacy disease-modifying drug for relapsing multiple sclerosis?

Source: [thelancet.com](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)02240-3/fulltext?rss=yes) · 2026-11-21 · Medicine
Page: https://themorning.science/story/comment-remibrutinib-a-high-efficacy-disease-modifying-drug-for-relapsing-multip-2d2808e8d586a4be
Kind: research · Impact: medium

## In brief

- A Lancet comment asks whether remibrutinib, a BTK inhibitor, can be a high-efficacy disease-modifying drug for relapsing multiple sclerosis.
- BTK inhibitors directly modulate B lymphocytes and myeloid cells, including macrophages and microglia.
- Because they act on both adaptive and innate immune mechanisms, BTK inhibitors target two sides of MS immunopathology.

## Why it matters

It reports on a possible new drug approach for relapsing multiple sclerosis, and science readers can track whether its mechanism translates into clinical efficacy.

## Timeline

- 2026-11-21: Lancet comment on remibrutinib for relapsing multiple sclerosis published

## Coverage

- [[Comment] Remibrutinib: a high-efficacy disease-modifying drug for relapsing multiple sclerosis?](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)02240-3/fulltext?rss=yes) — thelancet.com, 2026-11-21

Tags: multiple sclerosis, bruton tyrosine kinase, remibrutinib, neuroimmunology, disease-modifying therapy

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science
